Search For "bharat biotech"
Updated : 2 months, 2 weeks ago IST
Hyderabad (Telangana) [India], July 3 (ANI): Hyderabad-based Bharat Biotech on Saturday concluded a final analysis for its vaccine Covaxin efficacy from phase-3 clinical trial claiming it to be 77.8 per cent effective against COVID-19.
New Delhi [India], July 3 (ANI): The Congress Party on Friday cornered the central government over the Covaxin pricing controversy in Brazil and asked the Centre why it is "conspicuously silent" on the matter.
Updated : 2 months, 3 weeks ago IST
New Delhi [India], June 30 (ANI): Hyderabad-based vaccine manufacturer Bharat Biotech on Wednesday said that the company hopes to start manufacturing its COVID-19 vaccine Covaxin in Bengaluru soon.
New Delhi [India], June 30 (ANI): Results of trials of the third booster dose of Bharat Biotech's COVID-19 vaccine Covaxin is expected to come by November this year, sources told ANI.
Hyderabad (Telangana) [India], June 30 (ANI): Issuing clarification on COVAXIN pricing controversy in Brazil, Bharat Biotech on Tuesday said it followed a step-by-step regulatory approval process during the eight-month period, but the company has neither received any advance payments nor
Washington DC [US], June 30 (ANI): The National Institute of Health (NIH) in the United States has found that Bharat Biotech's COVAXIN vaccine generates antibodies that effectively neutralize both Alpha and Delta variants of COVID-19.
Brasilia [Brazil], June 30 (ANI): Amid a probe into accusations of irregularities against President Jair Bolsonaro, Brazil's health minister has announced that the country will suspend a USD 324 million contract to buy 20 million doses of Bharat Biotech's Covaxin.
Hyderabad (Telangana) [India], June 27 (ANI): Union Minister of State for Chemicals and Fertilisers Mansukh Mandaviya along with Minister of State for Home Affairs G Kishan Reddy on Sunday reviewed production of COVID-19 vaccines in Hyderabad.
Updated : 2 months, 4 weeks ago IST
New Delhi [India], June 23 (ANI): Noting that children usually have a mild disease but there is a need to develop COVID-19 vaccines for them, AIIMS Delhi Director Dr Randeep Guleria has said Bharat Biotech and other companies are doing trials at a very fast pace and hoped that data will l
New Delhi [India], June 22 (ANI): The Drugs Controller General of India (DCGI) is likely to approve Phase III trial data of Covaxin on Tuesday, sources said.
New Delhi [India], June 22 (ANI): Bharat Biotech's Covaxin has shown 77.8 per cent efficacy after the Subject Expert Committee (SEC) under the drug regulator reviewed its Phase III trials data on Tuesday, according to sources.
New Delhi [India], June 22 (ANI): The Subject Expert Committee (SEC) under the drug regulator will discuss reviewing the Phase III data of Bharat Biotech's Covaxin on Tuesday.